联合集团(00373) - 2024 - 年度业绩

Financial Performance - Total revenue for the year ended December 31, 2024, was HKD 7,848.0 million, a slight increase from HKD 7,831.4 million in 2023[4] - The company reported a net loss of HKD 712.3 million for the year, compared to a profit of HKD 256.0 million in the previous year[5] - Basic and diluted loss per share for the year was HKD 0.22, compared to a loss of HKD 0.04 in 2023[5] - The total comprehensive loss for the year was HKD 1,139.5 million, compared to a total comprehensive loss of HKD 446.5 million in 2023[7] - The pre-tax loss attributable to shareholders for 2024 was HKD 776.7 million, significantly higher than the loss of HKD 125.4 million in 2023[26] - The company did not declare any dividends for the fiscal year ending December 31, 2024, compared to HKD 412.9 million in dividends declared for 2023[27] - The total tax expense for 2024 was HKD 497.0 million, an increase from HKD 322.3 million in 2023[25] Operating Expenses and Income - Total operating expenses increased to HKD 5,139.0 million from HKD 5,055.0 million in 2023, reflecting a rise in administrative expenses[4] - The company recognized a gain of HKD 495.1 million from the bargain purchase of a subsidiary[4] - Financial asset impairment losses decreased to HKD 930.6 million from HKD 1,035.6 million in the previous year[4] - The impairment loss on financial assets for 2024 was HKD 930.6 million, a decrease from HKD 1,035.6 million in 2023, reflecting improved asset quality[23] - The company’s revenue from hospital fees and charges increased significantly to HKD 1,581.0 million in 2024 from HKD 394.2 million in 2023[16] Assets and Liabilities - Total non-current assets decreased from HKD 71,791.5 million in 2023 to HKD 65,235.5 million in 2024, a reduction of approximately 9.1%[8] - Current assets increased from HKD 42,018.1 million in 2023 to HKD 48,722.8 million in 2024, representing an increase of about 15.9%[9] - Total liabilities increased from HKD 27,778.0 million in 2023 to HKD 33,192.0 million in 2024, an increase of approximately 19.4%[9] - The company's total assets decreased from HKD 86,031.6 million in 2023 to HKD 80,766.3 million in 2024, a decrease of about 6.0%[9] - The company's equity attributable to shareholders decreased from HKD 43,538.9 million in 2023 to HKD 42,524.8 million in 2024, a decline of approximately 2.3%[9] Cash Flow and Financing - The company's cash and cash equivalents rose from HKD 14,702.0 million in 2023 to HKD 15,139.0 million in 2024, a growth of about 3.0%[8] - The company's debt totaled HKD 19,900.1 million, down from HKD 24,380.9 million in the previous year, with a significant reduction in short-term liabilities[44] - Total financing costs for 2024 amounted to HKD 1,231.2 million, a decrease of 5.5% from HKD 1,303.2 million in 2023[24] Investments and Acquisitions - The company acquired Tianan Health Limited on October 5, 2023, marking its first ownership of hospitals and other buildings in China[15] - The company committed to invest EUR 75.7 million and approximately EUR 49.6 million in a partnership enterprise focused on qualified investments[46] - The company has pledged USD 100 million to the WCD fund and AUD 25 million as cornerstone investment in Wentworth GP Trust[51] Market and Economic Conditions - The board remains vigilant regarding various risks and challenges in the market, including financial issues faced by large Chinese real estate developers and rising interest rates, which are expected to add downward pressure on the local property market[60] - The group welcomes measures implemented by central and local governments to stabilize the real estate market, which are expected to increase liquidity and stimulate the mainland Chinese economy[60] Employee and Operational Metrics - The total employee cost for the group was HKD 1,353.2 million, down from HKD 1,390.8 million in 2023, with a total employee count of 5,751 as of December 31, 2024[57] - The company plans to continue optimizing its capital structure to ensure sustainable operations and maximize shareholder returns[39] Miscellaneous - The audit committee has reviewed the accounting principles and financial statements for the year ending December 31, 2024[64] - The preliminary figures for the consolidated financial position and income statement have been approved by the board on March 26, 2025[65] - The company did not repurchase, sell, or redeem any shares during the year ending December 31, 2024[66] - Unclaimed dividends declared for over six years may be forfeited by the board and returned to the company[67] - Shareholders must claim any unreceived dividends by April 25, 2025, to avoid forfeiture[68] - The board expresses gratitude to employees for their efforts and contributions during the fiscal year 2024[69]